Find in Library

<p class="p1">Canadian nurses are familiar with biosimilars in general, but may have knowledge gaps in their specific understanding, resulting in a significant unmet need for education. To assist Canadian nurses in gaining a greater understanding of biosimilars within the oncology treatment landscape and to alleviate certain concerns regarding biosimilar agents, the objectives of this Supplement are to discuss:</p><ul><li>biologic drugs in general with an overview of their production</li><li>biosimilarity and biosimilars relative to reference biologic drugs</li><li>mechanisms of action: biosimilars versus reference biologic drugs</li><li>steps to biosimilar development<span class="Apple-converted-space"> </span></li><li>extrapolation of indications for biosimilars—“totality of evidence” for biosimilars</li><li>interchangeability and substitution</li><li>Health Canada’s approval process for biosimilars</li><li>the role of nurses in introducing biosimilars and monitoring patients</li></ul>